GSK (LSE:GSK) has been on investor radars after recent trading performance, with the share price showing a 1.1% decline over ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's ...

GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...

Shares of RAPT Therapeutics surged sharply on Tuesday after the biopharmaceutical company said it had agreed to be acquired ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain for ...

Investors with a lot of money to spend have taken a bearish stance on GSK (NYSE:GSK). And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...

The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

The acquisition was announced on Tuesday, News.Az reports, citing Reuters. This marks GSK's first major purchase under the ...

GSK plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and ...